Biotech and Pharmaceuticals Medicine


  • Roche & Genentech: Get It Together Wednesday, 6 May 2009 | 12:32 PM ET

    It's a new world. Before Roche bought Genentech, stock-moving drug development milestones for DNA were closely followed by the news media, analysts and investors. But because the Swiss drugmaker Roche only trades over-the-counter in the U.S., the information isn't as "actionable" as it used to be when DNA was around.

  • Battlin' Over Amylin Wednesday, 6 May 2009 | 11:07 AM ET

    You gotta love a good proxy fight, especially when you have one of the kings of shareholder activism, Carl Icahn, in the ring. And lately, I've been getting bombarded by emails from representatives of all corners.

  • Cinco de Mayo Para Byetta Tuesday, 5 May 2009 | 12:22 PM ET

    Fiesta time started a little earlier than expected for investors in Eli Lilly, Amylin Pharmaceuticals and Alkermes. The companies had said they would file for Food and Drug Administration approval of the once-a-week version of the diabetes drug Byetta in the second quarter, but most analysts thought that meant June.

  • May Day For Dendreon? Monday, 4 May 2009 | 11:05 AM ET

    Whenever a politician, government agency or company puts out news late on a Friday chances are it probably isn't good or it's stuff they'd like to just slip under the door.

  • Genentech's Desmond-Hellmann May Take Helm At UCSF Friday, 1 May 2009 | 3:37 PM ET
    Dr. Susan Desmond-Hellmann

    Well, it didn't take long. A little more than a month after Roche swallowed Genentech, Dr. Susan Desmond-Hellmann may be headed out the door sooner than anyone thought.

  • After Dendreon Week, Time For Lilly's LeWeekend Friday, 1 May 2009 | 10:05 AM ET

    have two reasons to exhale on this TGIF. My month-long stint on the graveyard shift anchoring "Worldwide Exchange" is over and Dendreon is done...for now. After all, Dendreon and its prostate cancer treatment Provenge is the story that just keeps on giving.

  • The Sequenom Syndrome Thursday, 30 Apr 2009 | 12:01 PM ET

    Shares of San Diego-based Sequenom are sinking on huge trading volume. The company shocked investors after the closing bell yesterday when it issued this press release announcing that its data couldn't be trusted.

  • The Morning After For Dendreon Wednesday, 29 Apr 2009 | 2:02 PM ET

    The herky-jerky, stop-and-go cab ride I'm taking right now to O'Hare ain't nuthin' compared to yesterday's roller coaster ride at Chicago's McCormick Place. And can I just say? Is Dendreon  a giant magnet for high drama and intrigue or what?

  • Feeding At The Swine Flu Trough Tuesday, 28 Apr 2009 | 9:31 AM ET

    Here we go again. When I was relatively new on this beat I was thrown into covering the bird flu scare. At the time, many experts said it wasn't a question of if, but when it would come to the U.S. I'm still waiting. And I hope we're all waiting forever.

  • Schering-Plough's Not Allergic To Discounts Monday, 27 Apr 2009 | 12:37 PM ET
    Nasonex Ad

    I didn't have much of a weekend. I was putting out swine flu fires via work emails and dealing with a really bad allergy attack. Plus, it kinda gets cut short by having to go to bed so early (6 o'clock) in order to anchor "Worldwide Exchange" at 4 a.m. ET.

  • Awaiting Proof on Provenge Friday, 24 Apr 2009 | 1:30 PM ET

    Next week's gonna be crazy, especially Tuesday aka "Dendreon Day." Shortly after I'm done anchoring "Worldwide Exchange" early Monday morning I'll be flying to Chicago to cover the highly anticipated data release on DNDN's Provenge. That's the name of the biotech company's unique, experimental treatment for prostate cancer.

  • Pfizer Shareholders & Its Rodent Get a Morsel Thursday, 23 Apr 2009 | 12:09 PM ET

    At Pfizer's annual shareholder meeting in Atlanta this morning, investors approved a version of "Say on Pay."

  • A Rare Failure For Roche's Avastin Wednesday, 22 Apr 2009 | 9:23 AM ET

    It's a good thing I'm working the graveyard shift this month anchoring "Worldwide Exchange" at four o'clock in the morning. It was about the time that I woke up to go to work today at 1 a.m. ET that Roche and Genentech sent out their press releases announcing that their cancer drug Avastin didn't meet the main goal of a study to see if it extended the lives of people with early stage colon cancer.

  • The ABC's of Lilly: Amylin, Byetta & Carl Monday, 20 Apr 2009 | 11:39 AM ET
    Byetta Needle

    Shortly after Eli Lilly reported way better than expected earnings this morning, Amylin Pharmaceuticals fired a new salvo in its escalating proxy battle with billionaire activist investor Carl Icahn.

  • Of Dendreon And Pfizer Shorts Friday, 17 Apr 2009 | 10:29 AM ET

    Not a surprise, but my post yesterday on what one reader called the analyst "flip-flop" on Dendreon generated a lot of responses and queries.

  • Analyst Eats Dendreon Crow Friday, 17 Apr 2009 | 9:51 AM ET

    As late as the day before the positive Dendreon data on its prostate cancer treatment Provenge came out, biotech analyst Jonathan Aschoff at Brean Murray Carret & Co. reiterated his "Sell" rating and $1 price target on the stock in a research note to clients. Today he's offering a bit of a mea culpa.

  • A Tweet Tip On Roche-Genentech Wednesday, 15 Apr 2009 | 10:55 AM ET

    In my less than five weeks on Twitter, I've gotten ideas for four blogs and late yesterday, for the first time, I got a legit news tip off a tweet (for the uninitiated, that's what the short messages sent on Twitter are called.)

  • Pfizer Gets Its Irish Up Tuesday, 14 Apr 2009 | 11:46 AM ET

    Oh, the fun the late-night comics could have with this one. The makers of the little blue pill are a little red-faced on the Emerald Isle.

  • What's Up With Dendreon? Monday, 13 Apr 2009 | 11:43 AM ET

    Dendreon is up yet again today on heavy volume. Several investors have emailed me and one analyst voicemailed me asking if I know what's going on. I don't. And I see no news.

  • The Beat Goes On With Merck & Cardiome Thursday, 9 Apr 2009 | 8:48 AM ET

    Victory for vernakalant! No, that's not German. It's the scientific, generic name of the experimental heart rhythm maintenance drug at a little Canadian company called Cardiome. The announcement came out Wednesday evening that Merck is hooking up with CRME in yet another partnership deal between big pharma and baby biotech.